**Table S1.** *Performance on Performance Validity Tests, and Subsequent Exclusions Across Close-range Blast Exposure and APOE ε4 Groups*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Variable | CBE-  APOE ε4- | CBE-  APOE ε4+ | CBE+  APOE ε4- | | CBE+  APOE ε4+ | | Group Comparison |
| *Sample size (n= 488)* | *n* = 210 | *n* = 66 | *n* = 162 | *n* = 50 | |  | |
| MVST & CVLT-II\*\* fails, n *(%)* | 1  *(.51%)* | 2  *(3.1%)* | 2  *(1.4%)* | 3  *(6.5%)* | | χ2(3) = 8.66, *p* = 0.03\* | |
| MVST Only\*\*  fails, n *(%)* | 9  *(4.4%)* | 2  *(3.1%)* | 6  *(4.0%)* | 1  *(2.2%)* | | χ2(3) = 0.620, *p* = 0.89 | |
| CVLT-II Only\*\*  fails, n *(%)* | 1  *(.50%)* | 0  *(0%)* | 6  *(3.9%)* | 0  *(0%)* | | χ2(3) = 9.00, *p* = 0.03\* | |
| CVLT-II FC, M (*SD*) | 99.5  *(2.34)* | 99.0  *(4.92)* | 98.8  *(4.15)* | 97.1  *(8.07)* | | (*F*(3,459) = 4.30, *p* < .01\*\*, ηp2 = .027 | |
| MSVT IR, M (*SD)* | 99.0  *(3.72)* | 98.6  *(5.63)* | 98.7  *(4.13)* | 97.2  *(6.88)* | | (*F*(3,463) = 2.09, *p* = .01\*\*, ηp2 = .013 | |
| MSVT DR, M (*SD)* | 98.2  *(5.07)* | 97.6  *(8.25)* | 98.2  *(4.79)* | 95.9  *(10.2)* | | (*F*(3,463) = 2.01, *p* = .11, ηp2 = .013 | |
| MSVT CNS, M (*SD)* | 97.9  *(5.65)* | 97.0  *(9.26)* | 97.7  *(4.74)* | 96.1  *(9.48)* | | (*F*(3,463) = 1.17, *p* = .32, ηp2 = .008 | |

Note. Group comparisons were done using analysis of variance (ANOVA) tests for continuous variables and χ2 test of association for categorical variables. \**p* < .05, \*\**p* < .01. Sample size is full sample before any exclusions. MSVT = Medical Symptom Validity Test. CVLT-II = California Verbal Learning Test-2nd Edition. CVLT-II FC = Percentage correct on Forced Choice trial of CVLT-II, MSVT IR, = Percentage correct on Immediate Recall trials of MSVT. MSVT DR = Percentage correct on Delayed Recall trials of MSVT, MSVT CNS = Percentage consistency of responding across Immediate Recall and Delayed Recalled on MSVT